Precision medicine, genetic profiling, targeted therapies
A three-stage customized journey to fight cancer
Every cancer is unique: understanding its deep nature is key to effectively fight it. Virtually all the tumors arise because of specific genomic alterations, driving cancer growth and making it different from any other. The tumor’s genetic profiling can identify the alterations in the cancer DNA, both in liquid and solid tumors.
Every cancer is unique: a targeted strategy is the best way to effectively fight it. By exploiting its highly qualified Scientific Committee, which integrates the genetic results with the clinical experience in targeted therapies, Medendi can find the right therapeutic options for every specific cancer type, and propose patients the best treatment solutions.
stage 1
Evaluation
By examining the patient’s clinical documentation, the Medendi Scientific Committee evaluates the opportunity to proceed with the genomic profiling of the tumor.
stage 2
Genomic profiling
Medendi arranges the genomic profiling test of the patient’s tumor, advising the most appropriate molecular test and managing the whole process with no stress for the patient.
stage 3
Recommendation
Building on the Member’s clinical experience, the Scientific Committee analyzes the genetic test results to indicate the most appropriate therapeutic options available, including clinical trials.
A patient story:
Andrea Bizzarri
Andrea’s tumor genomic profiling test has revealed a specific mutation, known to cause resistance to the therapy he was undergoing. These results allowed Andrea to shift immediately to a different treatment, known to be effective in this setting. This turned out the be the case.
Thanks to the consistent reduction in tumor volume, Andrea had a successful liver surgery in November 2020 and today he is disease-free (under maintenance therapy).
A journey
customized for
each patient
The patient is not required to move, and the full recommendation process takes on average 4 weeks.
The Evaluation process starts online by filling the contact form or scheduling a call with a Medendi Specialist; the clinical documentation is sent by email and Medendi replies in approximately three days.
The genetic profiling test is made on the same tissue sample used for diagnosis (the patient may obtain the sample from the treating anatomo-histopathology department) or using a few ml of a peripheral blood withdraw.
The Medendi Scientific Committee interprets the results of the genetic profiling and shares with the patient its recommendation for the most appropriate treatment options available. The genetic profiling + recommendation phase is completed in about 3 weeks.
More
services
Clinical trial matching
This is a service part of the Recommendation phase. However, this service can be offered independently to patients who already have genetic and/or molecular information and desire to explore this opportunity.
Second opinion
Asking for a second opinion may help the patient and the oncologist to confirm the ongoing therapeutical choices or identify alternative or integrative options. Medendi can directly provide a second opinion via the Scientific Committee or address the patient’s request to specialized excellence centers.
General assistance
Medendi supports the patients and the families in accessing the therapies provided by selected medical center and specialists. Medendi can offer a full-service assistance, providing support for general bureaucracy, documentation, and logistics, including the travel organization, accommodation, clinical check-in, and translators on-site.
Why
Medendi
Sequencing the tumor DNA will uncover the specific nature of the disease, but this is not enough. The experts’ scientific competences are key to turn the knowledge into the most effective treatment options. The Medendi process integrates advanced technologies, the highly qualified Scientific Committee, the possibility to access the most qualified centers and an effective co-operation with the oncologists.
Targeted therapies in centers of excellence
Based on the specific tumor genetic profile, the Medendi Scientific Committee recommends the patient with the centers of excellence where the most effective targeted treatments are available.
Clinical Trials
Worldwide
Medendi considers any therapeutical option, including the enrolment in clinical trials and the compassionate use of existing approved drugs.
An open relation
with patients
Medendi provides updates for any therapeutic option that may become available and engage with the patient and the trusted oncologists for any decision.
Hub of
oncology experts
Medendi is a hub for accessing exclusive competences and cutting-edge clinical centers for diagnosis, treatment, and follow-up of oncological diseases.
Professionalism
and experience
The Medendi Scientific Committee includes highly competent experts, members of trusted Italian and foreign research centers for oncology. Prof. Maurizio Scaltriti, Medendi Vice President, formerly Associate Director of Translational Science, Center for Molecular-Based Therapies – Memorial Sloan Kettering Cancer Center in New York, currently Vice President of Translational Medicine, Early Oncology – AstraZeneca, is coordinating the Scientific Committee and the assignment of the medical cases to the specialist members.
Founders
Maurizio Scaltriti
Founder
Scientific Advisor, VP
Associate Director of
Translational Science, Center
for Molecular-Based Therapies ›
Memorial Sloan Kettering
Cancer Center
Massimo Benassi
Co-Founder
Paolo Cavaggioni
Co-Founder
Finance and Legal
Giorgio Ferrari
Co-Founder
IT Infrastructures
Marco Marastoni
Co-Founder
Branding, Graphic Design
Giorgio Maugini
Co-Founder
Communication
Gianmarco Molinari
Co-Founder
Marketing